Use of prasugrel in a patient with clopidogrel hypersensitivity

Sarah R. Peppard, Bethanne M. Held-Godgluck, Richard Beddingfield

Research output: Contribution to journalArticlepeer-review

16 Scopus citations

Abstract

OBJECTIVE: To report a case of successful use of prasugrel following percutaneous coronary intervention with placement of a bare metal stent in a patient with a documented hypersensitivity reaction to clopidogrel. CASE SUMMARY: A 61-year-old male with a history of coronary artery disease with coronary stent placement presented with ST-elevation myocardial infarction. The patient had developed Stephens-Johnson syndrome 6 years earlier following clopidogrel administration, characterized by erythematous plaques and subsequent desquamation of the hands and feet; clopidogrel was discontinued and he was subsequently treated with ticlopidine in addition to aspirin. The third-generation thienopyridine prasugrel was initiated as a therapeutic alternative to clopidogrel after placement of a bare metal stent; a 60-mg dose was administered after extubation, followed by 10 mg/day. No signs of allergic reaction were observed in the days, weeks, and months following administration. DISCUSSION: Thienopyridines, specifically clopidogrel, are the standard of care for prevention of coronary stent thrombosis; however, there are few data available on cross-hypersensitivity between these agents. One study demonstrated that 27% of patients who developed an allergic or hematologic reaction to clopidogrel developed a similar reaction to ticlopidine. Other therapeutic options for patients with clopidogrel hypersensitivity who are undergoing a percutaneous coronary intervention with stent placement include clopidogrel desensitization, warfarin plus aspirin, cilostazol, ticagrelor, and ticlopidine. However, these options are limited by efficacy and/or toxicity. With its approval in 2009, prasugrel has become a potential treatment option. CONCLUSIONS: Prasugrel may be considered a therapeutic alternative in some patients allergic or intolerant to clopidogrel, but additional data are warranted to make a strong conclusion.

Original languageEnglish (US)
Pages (from-to)e54
JournalAnnals of Pharmacotherapy
Volume45
Issue number10
DOIs
StatePublished - Oct 1 2011

Keywords

  • Allergy
  • Clopidogrel
  • Hypersensitivity
  • Prasugrel
  • Thienopyridine

Fingerprint Dive into the research topics of 'Use of prasugrel in a patient with clopidogrel hypersensitivity'. Together they form a unique fingerprint.

Cite this